Press Releases

VANCOUVER, BC / ACCESSWIRE / May 6, 2024 / Silver Wolf Exploration Ltd. (TSXV:SWLF)(OTCQB: SWLFF) ("Silver Wolf" or the "Company") is pleased to announce that it has engaged Salman Partners Inc. to provide strategic advice to enhance shareholder value and awareness.

"We are absolutely thrilled to be working with Terry and the Salman Partners team" said Peter Latta President. "Terry has a tremendous reputation and expansive network in the mining industry that we believe... (continue reading...)

Highlights

• New best interval to date at Reid - 687 metres of 0.27% nickel including 36.0 metres of 0.41% nickel and 7.5 metres of 0.56% nickel in REI24-18.
• All four holes intersected core lengths of at least 676 metres with average grades of 0.24% to 0.27% nickel.

TORONTO, May 6, 2024 /PRNewswire/ - Canada Nickel Company Inc. ("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQX: CNIKF) provided an update today on its 2024 exploration program with assay results from... (continue reading...)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum... (continue reading...)

Contributes seed portfolio valued at $383 million to the JV, resulting in proceeds of approximately $300 million

Additional KKR capital commitment of up to $600 million to increase the potential value of the JV to more than $1 billion

NASHVILLE, Tenn., May 06, 2024 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE: HR) today announced that it has entered into a strategic joint venture (JV) relationship with KKR to jointly own and invest in... (continue reading...)

• Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soon
• Presented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and... (continue reading...)